FindTrial
Sign In

CELLECTRA™ 2000

DEVICE5 trials

Sponsors

Inovio Pharmaceuticals

Conditions

Human Papillomavirus (HPV)Lassa FeverMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)Pre-cancerous Lesions of the VulvaRespiratory PapillomatosisUrothelial CarcinomaVIN2VIN3

Phase 1

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
CompletedNCT03502785
Inovio PharmaceuticalsUrothelial Carcinoma
Start: 2018-05-24End: 2025-05-09Updated: 2025-07-10
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
CompletedNCT04093076
Inovio PharmaceuticalsLassa Fever
Start: 2021-01-27End: 2022-10-14Updated: 2022-11-21
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
CompletedNCT04398433
Inovio PharmaceuticalsRespiratory Papillomatosis
Start: 2020-06-15End: 2022-12-15Updated: 2024-09-19

Phase 2

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
CompletedNCT03180684
Inovio PharmaceuticalsHuman Papillomavirus (HPV), Pre-cancerous Lesions of the Vulva, VIN2 +4
Start: 2017-08-31End: 2020-12-18Updated: 2023-08-25
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
CompletedNCT04588428
Inovio PharmaceuticalsMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)
Start: 2021-06-21End: 2023-01-19Updated: 2026-01-22

Related Papers

Abstract A060: Treatment of Recurrent Respiratory Papillomatosis with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses in blood and airways of patients with clinical response Emma L
Cancer Immunology Research2026-02-18
Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers.
2025-11-14
Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.
2025-10-24
DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107
Nature Communications2025-02-1213 citations
Abstract A005: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways
Cancer Immunology Research2024-10-18
Interim Results of a Phase 1/2 <scp>Open‐Label</scp> Study of <scp>INO</scp>‐3107 for <scp>HPV</scp>‐6 and/or <scp>HPV</scp>‐11‐Associated Recurrent Respiratory Papillomatosis
The Laryngoscope2023-05-1930 citations
Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma
Cancer Research2019-07-011 citations
Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma
Clinical Trials2019-07-01